BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it is partnering with the University of Maryland, Baltimore (UMB) and the State of Maryland, through the Maryland Industrial Partnerships (MIPS) program, to develop a novel pharmaceutical product specifically aimed at preventing reperfusion injury associated with cardiac ischemia (heart attack). The State of Maryland is contributing $100,000 of the $232,000 per year to the project at UMB, with an agreement to provide second year funding upon successful completion of the first year’s goals. RegeneRx is contributing approximately $54,000 and retains the right to exclusively license all intellectual property developed under the project.
